ArticleLaboratory investigation; a journal of technical methods and pathology2026
Proteomic Profiling of Complement Components in Glomerular Disease.
Article in Laboratory investigation; a journal of technical methods and pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The complement system plays a central role in glomerular disease development and resolution. Currently, renal biopsies assess the presence of complement through limited immunofluorescence stains (C3 and C1q). With >50 total proteins and fragments involved in the complement cascade, this method offers a severely limited view into the mechanisms of tissue injury orchestrated by complement activation. A more comprehensive evaluation of complement components will advance the understanding of complement involvement in glomerular diseases by allowing for multiplex detection of complement cascade proteins and activation products, which can be achieved by mass spectrometry (MS). Data-independent acquisition MS was performed following extraction of proteins from tissue lysates, microdissected glomeruli, or protein G immunoprecipitates from residual kidney biopsy tissue. Cohorts included patients with lupus nephritis, membranous nephropathy and membranous lupus nephritis, diabetic glomerulosclerosis, C3 glomerulonephritis, and control biopsies. Abundances of complement components by MS correlated with immunofluorescence intensity of C1q on kidney biopsies. Increased abundances of complement classical, lectin, final common pathway, and regulatory proteins correlated with disease activity in lupus nephritis. Complement protein abundances of final common pathway components were heterogeneous between patients with the same disease state, including diabetic glomerulosclerosis and various forms of proliferative glomerulonephritis. Finally, complement proteins and their activation products can be mapped to determine which components are impacted among individuals and between disease states. In conclusion, complement proteins and some of their split products can be reliably measured by MS of kidney biopsies, which can enhance our understanding of complement-mediated tissue injury and heterogeneity in glomerular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.